Bausch Health Companies Inc. (BHC): Price and Financial Metrics


Bausch Health Companies Inc. (BHC): $27.27

-0.28 (-1.02%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

BHC POWR Grades


  • Growth is the dimension where BHC ranks best; there it ranks ahead of 99.89% of US stocks.
  • BHC's strongest trending metric is Stability; it's been moving up over the last 47 weeks.
  • BHC's current lowest rank is in the Momentum metric (where it is better than 14.65% of US stocks).

BHC Stock Summary

  • Bausch Health Companies Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 1.15% of US listed stocks.
  • BHC's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 99.98% of US stocks.
  • Bausch Health Companies Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 12.06%, greater than the shareholder yield of 82.74% of stocks in our set.
  • Stocks that are quantitatively similar to BHC, based on their financial statements, market capitalization, and price volatility, are EXPR, WMG, BGI, IMH, and JAKK.
  • BHC's SEC filings can be seen here. And to visit Bausch Health Companies Inc's official web site, go to www.bauschhealth.com.

BHC Valuation Summary

  • BHC's price/sales ratio is 1.2; this is 89.43% lower than that of the median Healthcare stock.
  • BHC's price/sales ratio has moved down 18 over the prior 243 months.
  • Over the past 243 months, BHC's price/sales ratio has gone down 18.

Below are key valuation metrics over time for BHC.

Stock Date P/S P/B P/E EV/EBIT
BHC 2021-08-31 1.2 -15.2 -8.1 -320.4
BHC 2021-08-30 1.2 -15.2 -8.1 -320.3
BHC 2021-08-27 1.2 -15.1 -8.1 -319.7
BHC 2021-08-26 1.2 -14.7 -7.8 -316.7
BHC 2021-08-25 1.2 -15.1 -8.0 -319.3
BHC 2021-08-24 1.2 -15.0 -8.0 -318.7

BHC Growth Metrics

  • The 5 year net income to common stockholders growth rate now stands at -412.01%.
  • The 2 year revenue growth rate now stands at -0.15%.
  • Its 2 year price growth rate is now at -19.73%.
Over the past 15 months, BHC's revenue has gone down $1.19e+08.

The table below shows BHC's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 8,478 1,488 -1,287
2021-03-31 8,042 1,293 -1,018
2020-12-31 8,027 1,111 -560
2020-09-30 8,038 951 -1,923
2020-06-30 8,109 1,210 -2,043
2020-03-31 8,597 1,349 -1,888

BHC's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • BHC has a Quality Grade of C, ranking ahead of 54.36% of graded US stocks.
  • BHC's asset turnover comes in at 0.276 -- ranking 162nd of 677 Pharmaceutical Products stocks.
  • CCXI, NBY, and AERI are the stocks whose asset turnover ratios are most correlated with BHC.

The table below shows BHC's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.276 0.714 -0.004
2021-03-31 0.259 0.714 0.006
2020-12-31 0.255 0.720 0.022
2020-09-30 0.250 0.721 -0.017
2020-06-30 0.252 0.725 -0.021
2020-03-31 0.265 0.729 -0.011

BHC Price Target

For more insight on analysts targets of BHC, see our BHC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $36.08 Average Broker Recommendation 1.61 (Moderate Buy)

BHC Stock Price Chart Interactive Chart >

Price chart for BHC

BHC Price/Volume Stats

Current price $27.27 52-week high $34.80
Prev. close $27.55 52-week low $14.86
Day low $27.09 Volume 2,658,400
Day high $27.59 Avg. volume 3,358,366
50-day MA $28.27 Dividend yield N/A
200-day MA $28.43 Market Cap 9.77B

Bausch Health Companies Inc. (BHC) Company Bio


Bausch Health Cos. Inc. (formerly) Valeant Pharmaceuticals is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter products, and medical devices, including contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices. The company was founded in 1983 and is based in Laval, Canada.


BHC Latest News Stream


Event/Time News Detail
Loading, please wait...

BHC Latest Social Stream


Loading social stream, please wait...

View Full BHC Social Stream

Latest BHC News From Around the Web

Below are the latest news stories about Bausch Health Companies Inc that investors may wish to consider to help them evaluate BHC as an investment opportunity.

Bausch Health files confidentially for IPOs of eye care business and medical aesthetics business

Bausch Health Cos. Inc. said Monday it has filed confidentially for the initial public offerings of its eye health business Bausch & Lomb, and its medical aesthetics business Global Solta. The company has not yet set terms for either deal, but expects them to completed on previously communicated timelines of the fourth quarter of 2021 or first half of 2022, based on market conditions. Shares were up 1.2% premarket and have gained 37% in the year to date, while the S 500 has gained 18.7%.

Yahoo | September 13, 2021

Bausch Pays $300M For Diabetes Drug Lawsuit: Reuters

Reuters reports that Bausch Health Companies Inc (NYSE: BHC ) will pay $300 million to settle an antitrust lawsuit related to illegally maintaining a monopoly on diabetes drug Glumetza. The FDA first approved Glumetza, a once-daily Full story available on Benzinga.com

Benzinga | September 10, 2021

Why Impel NeuroPharma Stock Blasted 27% Higher Thursday

A big sell-off in the stock is followed by a sudden bull rush, days after the company wins its first FDA approval.

Yahoo | September 9, 2021

Bausch to pay $300 million in antitrust suit over diabetes drug

Bausch Health Companies Inc has agreed to pay $300 million to settle an antitrust lawsuit accusing it of illegally maintaining a monopoly on the diabetes drug Glumetza, enabling a nearly 800% price hike in 2015. Lawyers for companies that bought Glumetza and filed the class action against Bausch disclosed the deal in a court filing Wednesday, asking U.S. District Judge William Alsup in San Francisco to approve it. "Plaintiffs are pleased with the settlement, which recovers for the class a very substantial portion of the overcharges that they suffered," Steve Shadowen, a lawyer for the purchasers, said in an email.

Yahoo | September 9, 2021

Bausch to pay $300 mln in antitrust suit over diabetes drug

Bausch Health Companies Inc has agreed to pay $300 million to settle an antitrust lawsuit accusing it of illegally maintaining a monopoly on the diabetes drug Glumetza, enabling a nearly 800% price hike in 2015. Lawyers for companies that bought Glumetza and filed the class action against Bausch disclosed the deal in a court filing Wednesday, asking U.S. District Judge William Alsup in San Francisco to approve it. "Plaintiffs are pleased with the settlement, which recovers for the class a very substantial portion of the overcharges that they suffered," Steve Shadowen, a lawyer for the purchasers, said in an email.

Yahoo | September 9, 2021

Read More 'BHC' Stories Here

BHC Price Returns

1-mo -2.47%
3-mo -6.67%
6-mo -11.20%
1-year 58.64%
3-year 9.43%
5-year 1.11%
YTD 31.11%
2020 -30.48%
2019 61.99%
2018 -11.12%
2017 43.11%
2016 -85.72%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8948 seconds.